{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:54:28Z","timestamp":1770411268062,"version":"3.49.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,12,15]]},"abstract":"<jats:p>Ranpirnase (Rap) is a cytotoxic ribonuclease (RNase) isolated from frog oocytes. Here we describe high antitumor activity of a novel immunotoxin, 2L-Rap-hLL1-\u03b34P, composed of 2 Rap molecules, each fused to the N terminus of the light chain of hLL1, an internalizing anti-CD74 humanized antibody. To reduce unwanted side effects, the constant region of hLL1 was changed from \u03b31 to \u03b34 and further to \u03b34P by replacing serine228 to proline to prevent the formation of a half immunoglobulin G (IgG) common for IgG4. In vitro, 2L-Rap-hLL1-\u03b34P retained RNase activity, specific binding to CD74, and was significantly more potent against CD74+ cell lines (Daudi, Raji, and MC\/CAR) than naked hLL1. In vivo, the pharmacokinetic profile of 2L-Rap-hLL1-\u03b34P was similar to that of naked hLL1. The maximum tolerated dose of 2L-Rap-hLL1-\u03b34P in severe combined immunodeficient mice (SCID) or BALB\/c mice was 50 \u03bcg per mouse. In Raji and Daudi Burkitt lymphoma xenograft models, treatment with a single 5 to 50 \u03bcg dose of 2L-Rap-hLL1-\u03b34P, given as early or delayed treatment, resulted in cures of most animals. Treatment with 2L-Rap-hLL1-\u03b34P was significantly better than all controls, including saline, naked hLL1, and nonspecific immunotoxin. In conclusion, 2L-Rap-hLL1-\u03b34P demonstrated excellent in vitro and in vivo efficacy and thus merits further consideration as a therapeutic for CD74+ tumors.<\/jats:p>","DOI":"10.1182\/blood-2005-03-1033","type":"journal-article","created":{"date-parts":[[2005,8,19]],"date-time":"2005-08-19T00:25:16Z","timestamp":1124411116000},"page":"4308-4314","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease\/anti-CD74 humanized IgG4 antibody immunotoxin"],"prefix":"10.1182","volume":"106","author":[{"given":"Chien-Hsing","family":"Chang","sequence":"first","affiliation":[{"name":"From the Immunomedics, Morris Plains, NJ, and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja","family":"Sapra","sequence":"additional","affiliation":[{"name":"From the Immunomedics, Morris Plains, NJ, and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sailaja S.","family":"Vanama","sequence":"additional","affiliation":[{"name":"From the Immunomedics, Morris Plains, NJ, and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"Hansen","sequence":"additional","affiliation":[{"name":"From the Immunomedics, Morris Plains, NJ, and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan D.","family":"Horak","sequence":"additional","affiliation":[{"name":"From the Immunomedics, Morris Plains, NJ, and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"From the Immunomedics, Morris Plains, NJ, and the Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111817294395800_REF1","doi-asserted-by":"crossref","unstructured":"Leland PA, Schultz LW, Kim B-Y, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A. 1998;95: 10407-10412.","DOI":"10.1073\/pnas.95.18.10407"},{"key":"2019111817294395800_REF2","doi-asserted-by":"crossref","unstructured":"Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J Biol Chem. 1991;266: 245-251.","DOI":"10.1016\/S0021-9258(18)52427-3"},{"key":"2019111817294395800_REF3","doi-asserted-by":"crossref","unstructured":"Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt W, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue Kinet. 1988;21: 169-182.","DOI":"10.1111\/j.1365-2184.1988.tb00855.x"},{"key":"2019111817294395800_REF4","doi-asserted-by":"crossref","unstructured":"Mikulski SM, Ardelt W, Shogen K, Berstein EH, Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst. 1990;82: 151-153.","DOI":"10.1093\/jnci\/82.2.151-a"},{"key":"2019111817294395800_REF5","doi-asserted-by":"crossref","unstructured":"Notomista E, Catanzano F, Graziano G, et al. Onconase: an unusually stable protein. Biochemistry. 2000;39: 8711-8718.","DOI":"10.1021\/bi000415x"},{"key":"2019111817294395800_REF6","doi-asserted-by":"crossref","unstructured":"Boix E, Wu Y, Vasandani VM, et al. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol. 1996;257: 992-1007.","DOI":"10.1006\/jmbi.1996.0218"},{"key":"2019111817294395800_REF7","doi-asserted-by":"crossref","unstructured":"Newton DL, Xue Y, Boque L, Wlodawer A, Kung HF, Rybak SM. Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy. Protein Eng. 1997;10: 463-470","DOI":"10.1093\/protein\/10.4.463"},{"key":"2019111817294395800_REF8","doi-asserted-by":"crossref","unstructured":"Kim B-M, Kim H, Raines RT, et al. Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun. 2004;315: 976-983.","DOI":"10.1016\/j.bbrc.2004.01.153"},{"key":"2019111817294395800_REF9","doi-asserted-by":"crossref","unstructured":"Wu Y, Saxena SK, Ardelt W, et al. A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem. 1995;270: 17476-17481.","DOI":"10.1074\/jbc.270.29.17476"},{"key":"2019111817294395800_REF10","unstructured":"Iordanov MS, Ryabinina OP, Wong J, et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanism different from inhibition of protein synthesis. Cancer Res. 2000;60: 1983-1994."},{"key":"2019111817294395800_REF11","doi-asserted-by":"crossref","unstructured":"Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ. Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem. 2002;277: 15142-15146.","DOI":"10.1074\/jbc.M108115200"},{"key":"2019111817294395800_REF12","doi-asserted-by":"crossref","unstructured":"Leung SO, Shevitz J, Pellegrini MC, et al. Chimerization of LL2, a rapidly internalizing antibody specific for B-cell lymphoma. Hybridoma. 1994;13: 469-472.","DOI":"10.1089\/hyb.1994.13.469"},{"key":"2019111817294395800_REF13","doi-asserted-by":"crossref","unstructured":"Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood. 2001;97: 528-535.","DOI":"10.1182\/blood.V97.2.528"},{"key":"2019111817294395800_REF14","doi-asserted-by":"crossref","unstructured":"Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002;20: 274-281.","DOI":"10.1200\/JCO.20.1.274"},{"key":"2019111817294395800_REF15","doi-asserted-by":"crossref","unstructured":"Mikulski SM, Grossman AM, Carter PW, Shogen K, Costanzi, JJ. Phase I human clinical trial of Onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol. 1993;3: 57-64.","DOI":"10.3892\/ijo.3.1.57"},{"key":"2019111817294395800_REF16","unstructured":"Vanama SS, Sapra P, Hansen HJ, Horak ID, Goldenberg DM, Chang C-H. Construction and characterization of two recombinant immunotoxins consisting of glycosylated and non-glycosylated ranpirnase fused to an internalizing anti-CD74 humanized IgG4 antibody [abstract]. Cancer Biother Radiopharm. 2004;19: 514."},{"key":"2019111817294395800_REF17","unstructured":"Vanama SS, Sapra P, Hansen HJ, Horak ID, Chang C-H, Goldenberg DM. Construction, characterization, and mammalian expression of an immunotoxin consisting of ranpirnase fused to a humanized anti-EGP-1 antibody, hRS7, as a potential therapeutic for prostate cancer. Proc Am Assoc Cancer Res. 2005;46: 160. Abstract 679."},{"key":"2019111817294395800_REF18","doi-asserted-by":"crossref","unstructured":"Roche PA, Teletski CL, Stang E, Bakke O, Long EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci U S A. 1993;90: 8581-8585.","DOI":"10.1073\/pnas.90.18.8581"},{"key":"2019111817294395800_REF19","doi-asserted-by":"crossref","unstructured":"Morton PA, Zacheis ML, Giacoletto KS, Manning JA, Schwartz BD. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol. 1995;154: 137-150.","DOI":"10.4049\/jimmunol.154.1.137"},{"key":"2019111817294395800_REF20","doi-asserted-by":"crossref","unstructured":"Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci U S A. 1988;85: 3975-3979.","DOI":"10.1073\/pnas.85.11.3975"},{"key":"2019111817294395800_REF21","doi-asserted-by":"crossref","unstructured":"Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci U S A. 1991;88: 3150-3154.","DOI":"10.1073\/pnas.88.8.3150"},{"key":"2019111817294395800_REF22","doi-asserted-by":"crossref","unstructured":"Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993;11: 403-450.","DOI":"10.1146\/annurev.iy.11.040193.002155"},{"key":"2019111817294395800_REF23","doi-asserted-by":"crossref","unstructured":"Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabeled antibodies to the MHC class-II invariant chain by B-cell lymphoma. Biochem J. 1996;320: 293-300.","DOI":"10.1042\/bj3200293"},{"key":"2019111817294395800_REF24","unstructured":"Govindan SV, Goldenberg DM, Elsamra SE, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med. 2000;41: 2089-2097."},{"key":"2019111817294395800_","unstructured":"Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with anti-CD74 antibody conjugated with 111indium, 67gallium, or 90yttrium. Clin Cancer Res. 2001;7: 1505-1510."},{"key":"2019111817294395800_","unstructured":"Griffiths GL, Mattes MJ, Stein R, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res. 2003;9: 6567-6571."},{"key":"2019111817294395800_REF27","doi-asserted-by":"crossref","unstructured":"Sapra P, Stein R, Pickett J, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11: 5257-5264.","DOI":"10.1158\/1078-0432.CCR-05-0204"},{"key":"2019111817294395800_REF28","doi-asserted-by":"crossref","unstructured":"Stein R, Qu Z, Cardillo T, et al. Anti-proliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104: 3705-3711.","DOI":"10.1182\/blood-2004-03-0890"},{"key":"2019111817294395800_REF29","doi-asserted-by":"crossref","unstructured":"Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res. 2004;10: 6606-6611.","DOI":"10.1158\/1078-0432.CCR-04-0182"},{"key":"2019111817294395800_REF30","unstructured":"Sapra P, Griffiths GL, Govindan SV, et al. Pharmacokinetics and tissue biodistribution of a doxorubicin-antibody (anti-CD74) conjugate, IMMU-110, in mice and tolerability of naked anti-CD74 in cynomolgus monkeys. Eur J Cancer Suppl. 2004;2: 88. Abstract 290."},{"key":"2019111817294395800_REF31","doi-asserted-by":"crossref","unstructured":"Losman MJ, Hansen HJ, Dworak H, et al. Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer. 1997;80(suppl): 2660-2666.","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2660::AID-CNCR43>3.0.CO;2-7"},{"key":"2019111817294395800_REF32","doi-asserted-by":"crossref","unstructured":"Sharkey RM, Motta-Hennessy C, Gansow OA, et al. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Int J Cancer. 1990;46: 79-85.","DOI":"10.1002\/ijc.2910460116"},{"key":"2019111817294395800_REF33","doi-asserted-by":"crossref","unstructured":"Basu A, Goldenberg DM, Stein R. The epithelial\/carcinoma antigen, EGP-1, recognized by monoclonal antibody RS7\u20133G11, is phosphorylated on serine 303. Int J Cancer. 1995;62: 472-479.","DOI":"10.1002\/ijc.2910620419"},{"key":"2019111817294395800_REF34","doi-asserted-by":"crossref","unstructured":"Mansfield E, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;80: 2020-2026.","DOI":"10.1182\/blood.V90.5.2020"},{"key":"2019111817294395800_REF35","doi-asserted-by":"crossref","unstructured":"Soler-Rodriguez A-M, Ghetie M-A, Ghetie N, Oppenheimer-Marks N, Uhr JW, Vitetta ES. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endotherlial cells: implications for vascular leak syndrome. Exp Cell Res. 1993;206: 227-234.","DOI":"10.1006\/excr.1993.1142"},{"key":"2019111817294395800_REF36","unstructured":"Kuan CT, Pai LH, Pastan I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin Cancer Res. 1995;1: 1589-1594."},{"key":"2019111817294395800_REF37","doi-asserted-by":"crossref","unstructured":"Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles. Trends Pharmacol Sci. 1993;14: 148-154.","DOI":"10.1016\/0165-6147(93)90199-T"},{"key":"2019111817294395800_REF38","doi-asserted-by":"crossref","unstructured":"Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A. 1999;96: 3957-3962.","DOI":"10.1073\/pnas.96.7.3957"},{"key":"2019111817294395800_REF39","doi-asserted-by":"crossref","unstructured":"Newton DL, Hansen HJ, Liu H, et al. Specifically targeting the CD22 receptor of human B-cell lymphoma with RNA damaging agents. Crit Rev Oncol Hematol. 2001;39: 79-86.","DOI":"10.1016\/S1040-8428(01)00116-0"},{"key":"2019111817294395800_REF40","unstructured":"Onda M, Nagata S, Tsutsumi Y, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxin leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 2001;61: 5070-5077."},{"key":"2019111817294395800_REF41","doi-asserted-by":"crossref","unstructured":"Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol. 1999;163: 6072-6077.","DOI":"10.4049\/jimmunol.163.11.6072"},{"key":"2019111817294395800_REF42","doi-asserted-by":"crossref","unstructured":"Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345: 241-247.","DOI":"10.1056\/NEJM200107263450402"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4308\/465578\/zh802405004308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4308\/465578\/zh802405004308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T07:12:57Z","timestamp":1683184377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/13\/4308\/133298\/Effective-therapy-of-human-lymphoma-xenografts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,15]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2005,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1033","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,15]]}}}